鼻夹预处理及口式呼吸训练对成人FESS术后躁动发生影响的研究

注册号:

Registration number:

ChiCTR1900024925 

最近更新日期:

Date of Last Refreshed on:

2019-08-18 18:14:16 

注册时间:

Date of Registration:

2019-08-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

鼻夹预处理及口式呼吸训练对成人FESS术后躁动发生影响的研究

Public title:

Effects of Preconditioning by nasal splint and mouth-breathing on Emergence Delirium after FESS in adults

注册题目简写:

English Acronym:

研究课题的正式科学名称:

鼻夹预处理及口式呼吸训练降低成人功能性内窥镜鼻窦手术术后躁动发生的研究:一项随机对照研究

Scientific title:

Preconditioning by nasal splint and mouth breathing training reduce emergence delirium after Functional Endoscopic Sinus Surgery in adults: a randomised controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

许红娇 

研究负责人:

许红娇 

Applicant:

Xu Hongjiao 

Study leader:

Xu Hongjiao 

申请注册联系人电话:

Applicant telephone:

+86 18917909818

研究负责人电话:

Study leader's
telephone:

+86 18917909818

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gillianxu1987@163.com

研究负责人电子邮件:

Study leader's E-mail:

gillianxu1987@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区海宁路100号上海第一人民医院12号楼3楼麻醉科

研究负责人通讯地址:

上海市虹口区海宁路100号上海第一人民医院12号楼3楼麻醉科

Applicant address:

100 Haining Road, Hongkou District, Shanghai, China

Study leader's address:

100 Haining Road, Hongkou District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海第一人民医院

Applicant's institution:

Shanghai General Hospital

研究负责人所在单位:

上海第一人民医院

Affiliation of the Leader:

Shanghai General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019KY039

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海第一人民医院人体试验审查委员会

Name of the ethic committee:

Ethics Committee of Shanghai General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2019-07-29 00:00:00

伦理委员会联系人:

耿雯倩

Contact Name of the ethic committee:

Geng Wenqian

伦理委员会联系地址:

上海市虹口区海宁路100号上海第一人民医院行政楼317室

Contact Address of the ethic committee:

Room 317, Administrative Building, Shanghai General Hospital, 100 Haining Road, Hongkou District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海第一人民医院

Primary sponsor:

Shanghai General Hospital

研究实施负责(组长)单位地址:

上海市虹口区海宁路100号上海第一人民医院12号楼3楼麻醉科

Primary sponsor's address:

100 Haining Road, Hongkou District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海第一人民医院

具体地址:

上海市虹口区海宁路100号

Institution
hospital:

Shanghai General Hospital

Address:

100 Haining Road, Hongkou District, Shanghai

经费或物资来源:

科室自筹

Source(s) of funding:

Self-raised marchds of departments

研究疾病:

全麻苏醒期躁动(术后躁动)  

Target disease:

Emergence agitation / Emergence delirium

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟采用鼻夹夹鼻的预处理的方式,于术前模拟鼻塞不适的感官并训练患者口式呼吸,研究其对成人FESS术后躁动发生的影响,旨在寻找一种预防FESS术后躁动的非药物手段。  

Objectives of Study:

In this study, was adopted to simulate the sensory discomfort by nasal splint and train mouth breathing, to study its influence on the occurrence of emergence agitation(ED) after FESS in adults, in order to find a non-drug means to prevent the ED after FESS.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1) 存在严重心血管系统疾病或血压控制不良
2) 存在精神疾病病史
3) 因任何原因服用镇静或精神类药物(神经抑制剂、抗焦虑药、抗抑郁药、苯二氮卓类药物)
4) 存在神经系统疾病病史(脑梗死、短暂性脑缺血发作、帕金森病、智力低下、颅脑损伤)
5) 鼻部畸形,鼻部外伤史,鼻部假体植入术后
6) 出现手术并发症(眼窝贯穿、大量出血需要输血或再次手术、脑脊液渗漏、眼睑气肿、眶内出血、脑膜炎、视力部分丧失、复视、失明、死亡)

Exclusion criteria:

1) With severe cardiovascular disease or poor blood pressure control;
2) history of mental illness;
3) taking sedatives or psychotics (neuroinhibitors, anti-anxiety drugs, antidepressants, benzodiazepines) for any reason;
4) history of neurological diseases (cerebral infarction, transient ischemic attack, Parkinson's disease, mental retardation, craniocerebral injury);
5) nasal malformation, history of nasal trauma, after the implantation of nasal prosthesis;
6) surgical complications (socket perforation, massive bleeding requiring blood transfusion or reoperation, cerebrospinal fluid leakage, eyelid emphysema, intraorbital bleeding, meningitis, partial loss of vision, double vision, blindness, death).

研究实施时间:

Study execute time:

From 2019-07-29 00:00:00 To 2021-07-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-07-29 00:00:00 To 2021-07-29 00:00:00

干预措施:

Interventions:

组别:

预处理组

样本量:

82

Group:

P-group

Sample size:

干预措施:

鼻夹

干预措施代码:

Intervention:

Nasal splint

Intervention code:

组别:

对照组

样本量:

82

Group:

C-group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai General Hospital

Level of the institution:

Tertiary A institution

测量指标:

Outcomes:

指标中文名:

镇静躁动评分

指标类型:

主要指标

Outcome:

The Sedation Agitation Scale

Type:

Primary indicator

测量时间点:

术后0-30分钟

测量方法:

观察

Measure time point of outcome:

0-30 mins after surgery

Measure method:

observe

指标中文名:

躁动分层评估

指标类型:

主要指标

Outcome:

The degree of agitation evaluation

Type:

Primary indicator

测量时间点:

术后0-30分钟

测量方法:

观察

Measure time point of outcome:

0-30 mins after surgery

Measure method:

observe

指标中文名:

疼痛评估

指标类型:

次要指标

Outcome:

Pain assessment

Type:

Secondary indicator

测量时间点:

术后0-30分钟

测量方法:

Measure time point of outcome:

0-30 mins after surgery

Measure method:

指标中文名:

疾病严重程度

指标类型:

附加指标

Outcome:

Severity of Illness

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用简单随机化分组,利用计算机产生随机数序列的方式将样本分成C组和P组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The participants will be divided into group C and group P by means of simple randomization group and random number sequence will be generated by computer using the IBM SPSS 20.0 software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

预计于2022年2月公布于中国临床试验注册中心的ResMan原始数据共享平台(IPD共享平台) http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data is expected to be released in February 2022 on the ResMan original data sharing platform (IPD sharing platform) of China clinical trial registry.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

上海第一人民医院HIS病例管理系统,IBM SPSS 20.0 进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Shanghai General hospital HIS case management system, IBM SPSS 20.0 for data management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-08-03 23:20:23